DACH1 Antibody

What is DACH1 and what are its biological functions?

DACH1 (Dachshund homolog 1) is a nuclear-localized transcription factor belonging to the DACH/dachshund protein family with a canonical form of 758 amino acids and a molecular weight of 78.6 kDa in humans . It plays a crucial role in regulating gene expression during organogenesis, particularly in eye development . DACH1 functions primarily as a transcriptional repressor by interacting with various co-factors to modulate signaling pathways.

The protein exerts significant influence on cellular processes through multiple mechanisms. DACH1 inhibits the TGF-beta signaling pathway through direct interactions with SMAD4 and NCOR1, which helps maintain proper cellular functions and prevents aberrant growth . Research has established DACH1 as a tumor suppressor in multiple cancer types, including breast cancer, where it blocks cellular proliferation and inhibits tumor growth .

What are the known isoforms of DACH1 and their functional differences?

DACH1 exists in up to four different isoforms produced through alternative splicing mechanisms . While the canonical isoform comprises 758 amino acids, the variant forms exhibit different structural compositions that may contribute to tissue-specific functions. These splicing variants potentially explain the diverse regulatory roles DACH1 plays across different tissues and cellular contexts .

The functional differences between these isoforms remain an active area of research, but evidence suggests they may interact with different binding partners, exhibit varied DNA binding affinities, or show differential regulation of downstream target genes. Understanding these isoform-specific functions is particularly important when designing experiments to study DACH1 in specific tissue or disease contexts.

How does DACH1 expression vary across different tissue types?

DACH1 is widely expressed across many tissue types, though expression levels vary significantly . Its expression is particularly notable in tissues where it plays critical developmental roles, including neural tissues and sensory organs. In adult tissues, DACH1 expression patterns often correlate with its role in maintaining tissue homeostasis.

In pathological contexts, DACH1 expression is frequently downregulated in various cancers, consistent with its tumor-suppressive role. For instance, reduced DACH1 expression in hypopharyngeal squamous cell carcinoma (HPSCC) tissues correlates with poor prognosis for patients . This downregulation appears to contribute to tumor progression through multiple mechanisms, including effects on the tumor microenvironment.

How does DACH1 regulate tumor progression and metastasis at the molecular level?

DACH1 inhibits tumor progression through multiple mechanisms that collectively suppress cancer cell proliferation, invasion, and metastasis. In breast cancer, DACH1 specifically inhibits cell invasion and metastasis by decreasing Matrix Metalloproteinase 9 (MMP9) expression . The molecular mechanism involves DACH1 repressing MMP9 transcription through two distinct interactions:

• DACH1 interacts with p65 at the NF-κB binding sites in the MMP9 promoter

• DACH1 interacts with c-Jun at the AP-1 binding sites in the MMP9 promoter

Furthermore, the association between DACH1 and p65 promotes the recruitment of HDAC1 (Histone Deacetylase 1) to the NF-κB binding site in the MMP9 promoter. This recruitment results in reduced acetylation levels and decreased transcriptional activity of p65, ultimately leading to decreased MMP9 expression . As MMP9 is a collagenase that degrades extracellular matrix (ECM) components including type 4 collagen, its downregulation by DACH1 inhibits the ability of cancer cells to invade surrounding tissues and metastasize.

In HPSCC, DACH1 inhibits cell proliferation, migration, and invasion via the Akt/NF-κB/MMP2/9 signaling pathway . Additionally, knockdown of DACH1 in FaDu cells has been shown to promote tumor progression through these mechanisms, confirming DACH1's tumor-suppressive role.

How does DACH1 influence the tumor microenvironment?

DACH1 plays a significant role in regulating the tumor microenvironment (TME), particularly through its effects on tumor-associated macrophages (TAMs). Research in HPSCC has revealed that decreased DACH1 expression is associated with fewer CD86+ TAMs (M1-like, anti-tumorigenic) and more CD163+ TAMs (M2-like, pro-tumorigenic) . This shift in macrophage polarization creates a microenvironment that favors tumor progression.

Mechanistically, DACH1 directly binds to the promoter region of IGF-1 (Insulin-like Growth Factor 1) to downregulate its secretion. Reduced IGF-1 secretion inhibits the polarization of TAMs to the pro-tumorigenic M2-like phenotype through the IGF-1R/JAK1/STAT3 signaling axis . In animal models, DACH1 inhibition has been confirmed to influence tumor progression and M2-like TAMs polarization, suggesting that IGF-1 is a critical downstream effector of DACH1 in regulating the TME.

This crosstalk between cancer cells and TAMs mediated by DACH1 represents a novel mechanism by which this transcription factor suppresses tumor progression, extending its known tumor-suppressive functions beyond direct effects on cancer cells themselves.

What signaling pathways are regulated by DACH1 in normal and pathological contexts?

DACH1 regulates multiple signaling pathways that control cell proliferation, differentiation, and survival in both normal development and pathological conditions. Key pathways affected by DACH1 include:

• TGF-β Signaling: DACH1 inhibits the TGF-β pathway through interactions with SMAD4 and the co-repressor NCOR1, regulating genes involved in cell growth and differentiation .

• NF-κB Signaling: DACH1 interacts with p65 to repress NF-κB-mediated transcription of targets like MMP9, affecting processes such as inflammation and cancer cell invasion .

• AP-1 Signaling: Through interaction with c-Jun, DACH1 modulates the activity of the AP-1 transcription factor complex, influencing the expression of genes involved in cell proliferation and migration .

• IGF-1 Signaling: DACH1 directly binds to the IGF-1 promoter to suppress its expression, subsequently affecting the IGF-1R/JAK1/STAT3 pathway that regulates macrophage polarization in the tumor microenvironment .

• Akt/NF-κB/MMP2/9 Pathway: In HPSCC, DACH1 regulates this pathway to inhibit cell proliferation, migration, and invasion .

These diverse signaling interactions highlight DACH1's role as a multifunctional regulator that coordinates complex cellular responses in development and disease.

What are the optimal conditions for DACH1 immunodetection?

For effective DACH1 immunodetection, researchers should consider the following optimized protocols based on experimental context:

Western Blotting (WB):

• Recommended antibodies: Mouse monoclonal antibodies like DACH1 Antibody (A-6) have demonstrated high specificity for DACH1 detection across human, mouse, and rat samples .

• Sample preparation: Nuclear extraction protocols are preferred due to DACH1's nuclear localization.

• Loading controls: Nuclear proteins like Lamin B or HDAC1 are appropriate controls rather than cytoplasmic housekeeping proteins.

• Expected molecular weight: Approximately 78.6 kDa for the canonical isoform, with additional bands possible for alternative isoforms .

Immunohistochemistry (IHC):

• Fixation: 10% neutral buffered formalin with optimal fixation time of 24 hours.

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) is typically most effective.

• Antibody concentration: Titration is recommended, starting with dilutions of 1:100-1:200.

• Detection systems: Polymer-based detection systems generally provide better signal-to-noise ratio.

• Counterstaining: Light hematoxylin counterstaining preserves nuclear DACH1 signal visualization.

Immunofluorescence (IF):

• Cell fixation: 4% paraformaldehyde for 15 minutes at room temperature.

• Permeabilization: 0.1-0.3% Triton X-100 for 10 minutes.

• Blocking: 5% normal serum from the species of the secondary antibody.

• Primary antibody incubation: Overnight at 4°C with antibodies validated for IF applications .

• Counterstaining: DAPI for nuclear visualization helps confirm the expected nuclear localization of DACH1.

What approaches are recommended for studying DACH1-protein interactions?

For investigating DACH1's interactions with other proteins, multiple complementary techniques should be employed:

Co-Immunoprecipitation (Co-IP):

• DACH1 antibodies conjugated to agarose beads, such as DACH1 Antibody (A-6) AC, are effective for pulling down DACH1 along with its binding partners .

• Reciprocal Co-IP (using antibodies against suspected binding partners like p65 or c-Jun) can confirm interactions from both perspectives.

• Nuclear extracts should be prepared with buffers containing appropriate salt concentrations (150-300 mM NaCl) to preserve physiologically relevant interactions.

Chromatin Immunoprecipitation (ChIP):

• For studying DACH1's interactions with DNA and associated proteins at specific genomic loci.

• ChIP-qPCR can verify DACH1 binding to specific promoters, as demonstrated in research showing DACH1 binding to the IGF-1 promoter .

• ChIP-seq provides a genome-wide view of DACH1 binding sites, helping identify novel targets.

Proximity Ligation Assay (PLA):

• Allows visualization of protein-protein interactions in situ with single-molecule sensitivity.

• Particularly useful for confirming DACH1 interactions with proteins like p65, c-Jun, SMAD4, or NCOR1 in their native cellular context.

Yeast Two-Hybrid and Mammalian Two-Hybrid Systems:

• For mapping interaction domains between DACH1 and its binding partners.

• Domain deletion or mutation constructs can identify specific regions of DACH1 responsible for particular protein interactions.

How can researchers quantify changes in DACH1 target gene expression?

To effectively measure changes in DACH1 target gene expression, researchers should employ these methodological approaches:

RT-qPCR (Reverse Transcription Quantitative PCR):

• Design primers spanning exon-exon junctions for target genes like MMP9.

• Use multiple reference genes for normalization (e.g., GAPDH, β-actin, and a tissue-specific stable gene).

• Calculate relative expression using the 2^(-ΔΔCt) method with appropriate statistical analysis.

Luciferase Reporter Assays:

• Construct reporters containing promoter regions of DACH1 target genes (e.g., MMP9 promoter).

• For detailed analysis, create reporter constructs with mutations in specific binding sites (NF-κB, AP-1) to determine their contribution to DACH1-mediated repression .

• Co-transfect with expression vectors for DACH1 and potential cofactors to assess combinatorial effects.

ChIP-qPCR:

• Target specific regulatory regions of genes suspected to be regulated by DACH1.

• Include analysis of histone modifications associated with active (H3K27ac, H3K4me3) or repressed (H3K27me3) chromatin states.

• Quantify DACH1 binding enrichment relative to input and IgG control samples.

RNA-seq with DACH1 Knockdown/Overexpression:

• Perform differential expression analysis between DACH1-modulated and control samples.

• Conduct pathway enrichment analysis to identify biological processes affected by DACH1.

• Validate key findings using RT-qPCR and protein-level assays.

How should researchers interpret contradictory DACH1 expression data across different studies?

When encountering contradictory DACH1 expression data across studies, researchers should systematically evaluate several key factors:

Antibody Specificity and Validation:

• Different anti-DACH1 antibodies may recognize different epitopes or isoforms, leading to discrepant results.

• Verify if antibodies used in contradictory studies were validated for specificity, particularly through methods like immunoblotting with DACH1 knockdown controls.

• Check if the antibodies recognize conserved regions present in all isoforms or if they target isoform-specific regions .

Tissue and Cell Type Considerations:

• DACH1 expression is context-dependent and varies across tissue types.

• Evaluate whether contradictory studies examined different cell types or cellular contexts where DACH1 might naturally have divergent functions.

• Consider the developmental stage of tissues, as DACH1 expression patterns change during development and differentiation.

Methodology Differences:

• Transcript vs. protein level detection: mRNA expression (detected by RT-qPCR or RNA-seq) may not always correlate with protein levels (detected by Western blot or IHC).

• Subcellular localization: Since DACH1 is a nuclear protein, sample preparation methods that fail to effectively extract or preserve nuclear proteins may yield false negatives.

• Quantification approaches: Different normalization methods or scoring systems, particularly in IHC studies, can lead to divergent interpretations of the same biological phenomenon.

Biological Complexity:

• DACH1 exists in multiple isoforms that may have context-dependent functions .

• Post-translational modifications may affect DACH1 detection or function without changing expression levels.

• DACH1 may exhibit biphasic effects in certain contexts, functioning differently at high versus low expression levels.

To resolve contradictions, researchers should consider performing parallel analyses using multiple detection methods and antibodies that target different DACH1 epitopes, while carefully controlling for cell type, culture conditions, and experimental procedures.

What are common pitfalls in DACH1 functional studies and how can they be avoided?

Researchers studying DACH1 function should be aware of these common pitfalls and implement corresponding mitigation strategies:

Incomplete Knockdown/Overexpression Validation:

• Pitfall: Relying solely on transcript-level validation for knockdown/overexpression studies.

• Solution: Confirm both mRNA and protein level changes, and verify subcellular localization of DACH1 in overexpression systems.

Isoform-Specific Effects:

• Pitfall: Attributing phenotypes to "DACH1" broadly without considering isoform-specific functions.

• Solution: Design experiments to discriminate between the four known isoforms, using isoform-specific knockdown or overexpression where possible .

Context-Dependent Function Misinterpretation:

• Pitfall: Generalizing findings from one cell type or tissue to all DACH1-expressing systems.

• Solution: Validate key findings across multiple cell lines or primary cultures and consider in vivo models for confirmation.

Pathway Crosstalk Oversight:

• Pitfall: Focusing on a single pathway (e.g., only examining NF-κB without considering AP-1 effects).

• Solution: Employ systems biology approaches and examine multiple interconnected pathways simultaneously, as DACH1 regulates both NF-κB and AP-1 pathways in breast cancer .

Microenvironment Considerations:

• Pitfall: Studying cancer cells in isolation without considering DACH1's effects on the tumor microenvironment.

• Solution: Incorporate co-culture systems with relevant stromal components, particularly macrophages which are affected by DACH1-regulated factors like IGF-1 .

Temporal Dynamics Neglect:

• Pitfall: Capturing only a single timepoint after DACH1 manipulation.

• Solution: Perform time-course experiments to distinguish primary from secondary effects, especially when studying signaling pathway perturbations.

By anticipating these pitfalls and implementing appropriate experimental designs, researchers can generate more robust and reproducible data on DACH1 function in their systems of interest.

What controls are essential when studying DACH1 in cancer models?

When investigating DACH1 in cancer models, the following controls are essential for generating reliable and interpretable data:

Expression Controls:

• Positive control: Include cell lines or tissues with verified high DACH1 expression (e.g., certain normal tissues) alongside experimental samples.

• Negative control: Use cell lines with confirmed low or absent DACH1 expression, or DACH1 knockout models.

• Isotype controls: For antibody-based detection methods, include appropriate isotype controls to assess non-specific binding.

Genetic Manipulation Controls:

• For knockdown studies: Compare DACH1-specific siRNA/shRNA with scrambled sequences and validate knockdown efficiency at both mRNA and protein levels.

• For overexpression studies: Utilize empty vector controls and verify physiologically relevant levels of DACH1 expression.

• Rescue experiments: Perform rescue with wild-type DACH1 after knockdown to confirm phenotype specificity.

Pathway Analysis Controls:

• Include known pathway activators/inhibitors as positive controls when studying DACH1's effects on specific signaling pathways.

• For studies on DACH1's regulation of MMP9, include TNF-α treatment as a positive control for MMP9 induction .

• When examining macrophage polarization effects, include established M1 and M2 polarization stimuli as reference controls .

Functional Assay Controls:

• Migration/invasion assays: Run parallel assays with cells of known high and low invasive capacity.

• For tumor microenvironment studies: Include monocultures alongside co-cultures to distinguish direct and indirect effects.

• In vivo models: Use appropriate syngeneic or xenograft controls, and consider orthotopic versus subcutaneous implantation based on the cancer type being studied.

Technical Controls:

• For ChIP experiments: Include input chromatin, IgG immunoprecipitation controls, and positive control loci (known DACH1 targets).

• For Co-IP: Perform reverse immunoprecipitation and include non-interacting protein controls.

• For microscopy: Include appropriate fluorophore controls and quantify data using objective, automated methods.

Implementing these comprehensive controls ensures that observed phenotypes can be confidently attributed to DACH1-specific mechanisms rather than experimental artifacts or non-specific effects.

What are emerging therapeutic applications of DACH1 in cancer research?

DACH1's established role as a tumor suppressor presents several promising therapeutic avenues that researchers are actively exploring:

Targeted DACH1 Restoration Approaches:

• Development of epigenetic modifiers to reverse DACH1 promoter hypermethylation in cancers where this is a silencing mechanism.

• Exploration of small molecules that can stabilize existing DACH1 protein or enhance its transcriptional repressor functions.

• Design of DACH1 gene therapy delivery systems for tumors with reduced DACH1 expression.

DACH1-Regulated Pathway Interventions:

• Targeting the IGF-1R/JAK1/STAT3 axis in tumors with low DACH1 expression to counteract the effects of DACH1 loss on macrophage polarization .

• Development of combination therapies targeting both DACH1-deficient tumor cells and their associated tumor microenvironment.

• MMP9 inhibitors as a downstream approach for tumors with DACH1 deficiency, given DACH1's repressive effect on MMP9 expression .

Biomarker Applications:

• DACH1 expression status as a prognostic biomarker, particularly in HPSCC where it correlates with patient outcomes .

• Development of companion diagnostics measuring DACH1 levels to identify patients likely to respond to specific therapeutic approaches.

• Multi-marker panels combining DACH1 with related pathway components to improve prognostic accuracy.

Regulatory T Cell and Macrophage Modulation:

• Exploitation of DACH1's role in regulating macrophage polarization to develop immunotherapeutic approaches .

• Investigation of how DACH1 status affects response to existing immunotherapies like immune checkpoint inhibitors.

As research continues to elucidate DACH1's complex roles in different cancer types, these therapeutic approaches will likely be refined with increased targeting specificity and efficacy.

How can single-cell approaches advance our understanding of DACH1 function?

Single-cell technologies offer unprecedented opportunities to resolve DACH1's context-dependent functions:

Single-Cell Transcriptomics:

• Enables identification of cell types and states where DACH1 expression is critical within heterogeneous tissues.

• Allows temporal mapping of DACH1 expression changes during cellular differentiation or malignant transformation.

• Facilitates discovery of cell type-specific DACH1 target genes by correlating DACH1 expression with gene expression patterns at single-cell resolution.

Single-Cell Epigenomics:

• Single-cell ATAC-seq can reveal how DACH1 affects chromatin accessibility across different cell populations.

• Single-cell ChIP-seq approaches may identify cell type-specific binding patterns of DACH1 to target genes.

• Integration with transcriptomic data can elucidate how DACH1-mediated epigenetic changes correlate with gene expression alterations in specific cellular contexts.

Spatial Transcriptomics/Proteomics:

• Allows visualization of DACH1 expression patterns in their native tissue context, preserving spatial relationships.

• Facilitates analysis of how DACH1-expressing cells interact with their microenvironment, particularly relevant given DACH1's effects on tumor-associated macrophages .

• Enables identification of spatial niches where DACH1 expression correlates with specific cellular phenotypes or microenvironmental features.

Lineage Tracing Combined with Single-Cell Analysis:

• Can track the fate of DACH1-expressing cells during development or cancer progression.

• May reveal how fluctuations in DACH1 expression affect cell fate decisions and phenotypic plasticity.